ObsEva SA

A previous regulatory setback in the US for Kissei Pharmaceutical Co., Ltd ’s female health product linzagolix has not discouraged the Japanese firm from continued development of the oral gonadotropi

Kronos Bio, Inc. implemented a restructuring plan in November that resulted in a 19% workforce reduction but extended its cash runway into 2026 and the company unveiled further cost cuts on 7 March t

The US Food and Drug Administration is urgently seeking patients that have experienced preterm birth with the market now devoid of treatments and a workshop on developing new therapies upcoming. A 30

At a time when the biopharma industry is still suffering from the financing hangover of 2022, investment in women’s health is on the upswing. While company founders, investors and scientists have been